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Abstract
Objectives: To analyze the impacts of pharmaceutical sector policies implemented to contain country spending
during the economic recession – a reference price system in Finland and a mix of policies including changes in
reimbursement rates, a generic promotion campaign and discounts granted to the public payer in Portugal – on
utilization of, as a proxy for access to, antipsychotic medicines.
Methodology: We obtained monthly IMS Health sales data in standard units of antipsychotic medicines in Portugal
and Finland for the period January 2007 to December 2011. We used an interrupted time series design to estimate
changes in overall use and generic market shares by comparing pre-policy and post-policy levels and trends.
Results: Both countries’ policy approaches were associated with slight, likely unintended, decreases in overall use of
antipsychotic medicines and with increases in generic market shares of major antipsychotic products. In Finland,
quetiapine and risperidone generic market shares increased substantially (estimates one year post-policy compared
to before, quetiapine: 6.80% [3.92%, 9.68%]; risperidone: 11.13% [6.79%, 15.48%]. The policy interventions in Portugal
resulted in a substantially increased generic market share for amisulpride (estimate one year post-policy compared
to before: 22.95% [21.01%, 24.90%]; generic risperidone already dominated the market prior to the policy interventions.
Conclusions: Different policy approaches to contain pharmaceutical expenditures in times of the economic recession
in Finland and Portugal had intended – increased use of generics – and likely unintended – slightly decreased
overall sales, possibly consistent with decreased access to needed medicines – impacts. These findings highlight
the importance of monitoring and evaluating the effects of pharmaceutical policy interventions on use of medicines
and health outcomes.
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Background
The current economic recession, which started in 2009,
has led many European countries – especially the Southern
and Mediterranean countries – to introduce austerity
measures primarily in public sectors such as publicly
funded health care systems. In the pharmaceutical sec-
tor, European social security systems face the difficult
task of guaranteeing their citizens equitable and sustain-
able access to needed medicines while containing ever-
rising pharmaceutical sector expenditures [1-4]. Ideally,
pharmaceutical sector cost-containment policies would
result in increased efficiency of spending, without limit-
ing access to needed medicines [5].
European systems have chosen different strategies to
contain medicines expenditures [6-9]. Changes in patient
co-payments for and increases in value-added taxes
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implemented cost-containment measures in 2010 [10].
These measures tend to shift cost-burden to those who
need medicines. Pharmaceutical sector cost-containment
policies may thus achieve financial savings for the public
health system, and may also have unintended effects in
the form of decreased utilization of needed medicines
when patients cannot afford to pay a higher share of
medicines costs [11-16].
Antipsychotic medications are essential for treatment
of severe chronic mental illness, such as schizophrenia,
bipolar disorder and autistic disorders, which are among
the leading major chronic diseases in Europe [17,18]. In
addition, off-label use of antipsychotic medicines is com-
mon for posttraumatic stress disorder, anxiety, attention
deficit hyperactivity disorder and mood disorders. Due
to their high cost, antipsychotic medications represent a
large component of public spending on medicines and
are therefore a frequent target of cost-containment pol-
icies. Reimbursement restrictions may, however, force
patients to forego treatment in light of increased out-of-
pocket payments [19] or to shift to other possibly less
appropriate or more costly treatments [20]. For example,
Soumerai et al. found that a policy that required prior
approval for reimbursement of specific atypical antipsy-
chotics to control expenditures in one US state public
insurance program resulted in increased rates of discon-
tinuity of antipsychotic drug treatment [21]. These re-
sults are consistent with an earlier study of the effects of
other policies on discontinuation of antipsychotic agents
among patients with severe mental illness [22].
Our intent was to assess the impacts of different cost-
containment policies implemented during the recession
in Finland and Portugal on antipsychotic utilization
within each country and to compare the magnitude of
effects. The recent recession affected both countries differ-
ently. Finland did not experience major declines in gross
domestic product (GDP) during the recession. Portugal,
however, suffered a 2.9% decline in GDP growth between
2008 and 2009 and another decline of 1.7% between 2010
and 2011 [23] leading to a strict three year public budget
savings plan between the Portuguese Ministry of Finance
and the Troika (consisting of representatives of the
European Commission, the European Central Bank and
the International Monetary Fund) [24]. We focus on
antipsychotic medicines, which are included in the pub-
lic reimbursement systems in both countries, because of
the public health relevance of antipsychotic disorders
and their treatment.
On April 1, 2009, Finland implemented a reference
price system whereby all medicines with therapeutic alter-
natives on the National Social Security’s reimbursement
list were clustered according to therapeutic similarity
based on each medicine’s indication and pharmacology.
Medicines in clusters were considered substitutable. For
each substitution group, a reference price was set at the
price of the least expensive medicine in the cluster, with
patients having to pay the difference for higher cost medi-
cations out-of-pocket. Danzon et al. highlighted that a
hoped-for effect of reference pricing is that manufacturers,
anticipating shifts to less expensive (mostly generic) prod-
ucts, decrease prices to not lose customers [25]. Accord-
ing to Pohjolainen et al., the average price level for all
medications decreased significantly in the first four quar-
ters after the implementation of the reference price system
in Finland, which led to 109 million Euro savings [26,27].
In addition to establishing reference pricing, the National
Social Security Scheme delisted the antipsychotic brand
product Seroquel (quetiapine) from its reimbursement
scheme on January 1, 2009, because the manufacturer did
not decrease its price to that of the 40% less expensive
generics when they became available [28,29].
In contrast, Portugal introduced several contemporan-
eous cost-containment policies: on October 15, 2010,
the Portuguese National Authority for Medicines and
Health Products (INFARMED) harmonized the reim-
bursement rates for antipsychotic medicines to 90% of
charges [30,31]. Prior to the change, antipsychotic medi-
cines were reimbursed at 37%, but in reality all patients
received antipsychotic medicines for free as physicians
could state certain pathologies (as listed in the legislation)
on the prescription for which antipsychotic medicines
were dispensed to the patient without co-payment. Fol-
lowing the change in reimbursement rates, no indication-
specific co-payment exemptions were allowed. In addition,
from September 15 to October 8 2010, INFARMED
launched a television and radio campaign to promote ge-
nerics (“you save, we all save”), informing the public about
the preferred use of generics due to lower prices of ge-
nerics as compared to originals [32]. Finally, on October
15, 2010 a 6% deduction of the maximum retail price took
effect for medicines that had not already lowered prices
earlier; this deduction did not affect the final consumer
price and is a statutory discount granted by industry and
supply chain actors to the public payer [33]. In the begin-
ning of 2013 this deduction was still applied.
We hypothesized that the implementation of the ref-
erence price system and delisting of the brand product
Seroquel in Finland, targeting product prices, would
lead to an increase in the proportion of sales (by vol-
ume) of generics, but likely no reduction in overall
utilization, that is, likely not pose barriers to anti-
psychotic medicines access. We hypothesized that the
change in reimbursement rates in Portugal would lead
to an unintended decrease in sales by volume of anti-
psychotic medications, because patients incurred higher
co-payments after the policy changes, which would con-
stitute a barrier to access for some. Finally, we expected
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result of the generic campaign.
Method
Data source
We analyzed monthly pharmaceutical sales in Finland
and Portugal between January 2007 and December 2011
provided by IMS Health [34]. Data are generated
through audits of aggregated purchases of registered
medicines by retail pharmacies from wholesalers in each
country. IMS audits cover 812 pharmacies or 100% of
the retail market in Finland and 2,910 pharmacies or
99% of the retail market in Portugal. IMS MIDAS com-
bines national audits into a globally consistent view of
pharmaceutical markets [35]. IMS Health collects data on
original products, generics identified by a brand name, ge-
nerics identified by INN name with company name as a
prefix or suffix and INN unbranded generics. Documenta-
tion on the IMS data collection and validation process is
available upon request from the authors. Antipsychotic
medicines were those in Anatomical Therapeutic Chem-
ical (ATC) category N5A of the European Pharmaceutical
Research Association (EphMRA) [36]. A detailed list of all
products included in the study is attached in Additional
file 1.
We extracted information on policy changes in each
country from the WHO Collaborating Centre for Pharma-
ceutical Pricing and Reimbursement Policies (PPRI) and
the IMS PharmaQuery databases. In addition, information
on policy changes was verified by national experts from
Finland and Portugal through written communication.
Outcome measures
We used two outcome measures for access: total volume
of antipsychotic medicines per capita and percentage
market share by volume in a therapeutic class. For the
total volume analyses, we divided the total number of
standard units (SU) sold per month by size of the na-
tional population to control for population growth, using
annual populations estimated from the Organization for
Economic Co-operation and Development (OECD) [36].
Our analyses included prescription-only antipsychotic
medicines limited to the retail market, which repre-
sented 98% of antipsychotic medicines sales by volume
in Portugal and 87% in Finland in 2011. A standard unit,
as defined by IMS Health, is the smallest dose of a prod-
uct, equivalent to one tablet or capsule for an oral
dosage form, one teaspoon (i.e. 5 ml) for a syrup and
one ampoule or vial for an injectable product. For the
purpose of this study we grouped all types of generics
(branded and unbranded) under the group “generics”
and contrasted them with originator brand product use.
We did so since only few unbranded generics were on
the countries’ markets and followed the same trends as
branded generics. We did no separate analyses of first
versus second generation antipsychotic (SGA) medicines
since the majority of products sold and the top selling
products in each country were SGAs. Percent market
share is the percent of total volume in the retail market
for each active substance in two categories – originator
brand products, which can be protected or no-longer-
protected by patents depending on their exclusivity
status in each period and country, and generic products
which are not subject to patent protection.
Study design and data analysis
We used an interrupted time series design, the strongest
quasi-experimental design [37], to estimate changes in
sales attributable to the policies by comparing sales after
the interventions to estimated sales based only on pre-
policy levels and trends (the counterfactual). We used
segmented regression models to statistically estimate
aggregate changes in levels and trends of monthly sales
by volume from the pre-policy period to the post-policy
period. Each model included a term to estimate the
baseline trend, a binary indicator for all post-policy
months to estimate the immediate level change in the
outcome measure following the policy change, and a
term indicating the number of months after policy
implementation to estimate the change in trend (slope)
during the post-policy period. The combined change in
level and trend at a given month after the policy repre-
sented the full policy effect. To allow for the possibility
of an anticipatory response to implementation of the
policy, we considered a phase-in period of four months
prior to the policy intervention in both countries and
excluded these four data points from the time-series
models [38-41]. We performed a sensitivity analysis by
comparing results from interrupted times series models
without a phase-in period. As the results were similar
we display only the results from the models with a
phase-in period. Further, we estimated absolute changes
from the counterfactual one year after the policy inter-
vention. We performed the analyses in SAS 9.3 and used
a stepwise selection approach, which removed non-
significant predictors (p>=0.2) from the model in order
of least significance.
Results
The antipsychotic market in Finland was dominated by
three leading active substances: quetiapine (31%), cloza-
pine (12%) and risperidone (12%), based on aggregated
sales by volume from 2007 to 2011. In Portugal, risperi-
done (17%), quetiapine (17%) and amisulpride (12%)
were the top three active substances sold in the class
during that period.
Figure 1(a,b) and Table 1 show the total monthly sales
of antipsychotics in standard units per capita in both
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reference price system, antipsychotic sales were increas-
ing by 704 SU (95% CI: 519, 889) per 100,000 people
per month; after the policy intervention, sales growth
decreased by 273 SU (95% CI: −572, 26) per 100,000
people per month compared to pre-policy sales growth.
There was no discontinuity in level of sales at the time
of intervention. This resulted in an estimated, not statis-
tically significant reduction of 3,550 SU (95% CI: −7,354,
254) per 100,000 people in actual sales compared to pre-
dicted sales (or around 2.3% of predicted sales) one year
after the implementation of the reference price system. In
Portugal, sales remained constant prior to the policies;
however after the policy interventions, there was an
estimated, statistically significant decrease in level of
antipsychotic sales of 4,686 SU (95% CI: −8,913, −458) per
100,000 people (or 4.5% of predicted sales), which
remained constant in the year after the policy.
Figure 2(a,b) displays the time series of generic market
shares as percentage of total standard units for the three
leading antipsychotic substances in each country. We ex-
amined quetiapine, clozapine and risperidone in Finland
Figure 1 Interrupted time series of the total retail antipsychotic markets in (a) Finland and (b) Portugal. Observed values and interrupted
time series estimates of the total retail antipsychotic market volume (standard unit per 100,000 persons per month) before and after the phase-in
period of the policy interventions in Finland and Portugal. Data source: IMS MIDAS®, January 2007 and December 2011, IMS Health Incorporated.
All Rights Reserved.
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no generic quetiapine products on the market in
Portugal at the time of the intervention.
In Finland, retail generic market share of all three anti-
psychotic substances was around 20% prior to the imple-
mentation of the reference price system with rapidly
increasing generic market shares of risperidone (2.19%
(95% CI: 2.03%, 2.34%) per month) and quetiapine
(2.07% (95% CI: 1.97%, 2.17%) per month), while the
increase in clozapine generic market share remained
low (0.07% per month (95% CI: −0.02, 0.17)). After the
implementation of the reference price system and the
delisting of Seroquel, the generic market share of quetia-
pine increased abruptly by 33.61% (95% CI: 31.62%,
35.61%); accompanied by a decrease in market share
growth of 2.06% (95% CI: −2.18%, −1.95%) per month,
which resulted in an estimated increase of 6.80% (95%
CI: 3.92%, 9.68%) generic market share one year after
the policy implementation period. A similar abrupt shift
to generics was seen for risperidone. After the introduc-
tion of the reference price system, there was an immedi-
ate increase of 37.65% (95% CI: 34.60%, 40.69%) in
generic market share accompanied by a decrease in
slope of 2.04% (95% CI: −2.20%, −1.88%) per month,
which resulted in a generic market share that continued
to increase slightly during the post-policy period. One
year after implementation, we estimated an increase of
11.13% (95% CI: 6.79%, 15.48%) in generic market share
due to the policies. Post-policy changes in generic mar-
ket shares for clozapine were relatively minor compared
to the other two active substances. After the introduc-
tion of the reference price system, there was a slight in-
crease of 2.22% (95% CI: 0.30%, 4.14%) in generic
market share accompanied by a slight decrease in slope
of 0.25% (95% CI: 0.36%, −0.13%) per month, resulting
in an estimated decrease of 0.97% (95% CI: −3.75%, −1.81%)
generic market share one year post-policy.
In Portugal, the generic market prior to the multifaceted
policy changes looked quite different from that in Finland.
Generic market shares for amisulpride remained between
10% and 20% throughout the pre-policy period with no in-
creasing trend, while the generic market share of risperi-
done was already around 90% prior to the policy. After
implementation of the policies, there was an immediate
increase in generic market share of 12.23% (95% CI:
9.61%, 14.85%) for amisulpride and an increase in market
share trend of 0.82% (95%: 0.56%, 1.09%) per month,
resulting in an estimated increase of 22.95% (95% CI:
21.01%, 24.90%) in total generic market share one year
after the policy intervention. The market for risperidone
had already been almost entirely generic prior to the reim-
bursement policy. After the policy, there was an estimated
increase in generic market share of 2.16% (95% CI: 0.76%,
3.57%) and an increase in trend of 0.19% (95% CI: 0.06%,
0.31%) per month, resulting in an estimated increase of
4.59% (95% CI: 2.67%, 6.51%) in total generic market
share one year after the policy mix. Details of the time
series estimates and confidence intervals are summa-
rized in Table 1.
Discussion
Our analyses showed that both countries’ policy ap-
proaches were associated with an increased market share
of generics as expected, but also with a likely unintended
slight decrease in overall use of antipsychotic medicines,
which may have been even more problematic against the
background of increased need of antipsychotic medicines
as a consequence of the economic recession. The decrease
in overall use was expected in Portugal, but somewhat
unexpected in Finland. In Finland two of the three leading
active substances in the antipsychotic class (quetiapine
and risperidone) experienced substantial increases in gen-
eric market share, but not the third substance (clozapine).
In contrast, in Portugal the combination of policies which
Table 1 Estimates of baseline trend, level and trend changes, and absolute changes one year after the policy
interventions for total antipsychotic sales and for generic market share of major active substances in Finland and
Portugal
Variable Monthly baseline
trend pre-policy
Level change
post-policy
Monthly trend
change post-policy
Absolute estimated
change one year
post-policy
(unit) (95% CI) (95% CI) (95% CI) (95% CI)
Finland
Total sales growth per 100,000 population (SU) 704 (519, 889) - -273 (-572, 26) -3550 (-7354, 254)
Quetiapine generic market share (%) 2.07(1.97, 2.17) 33.61(31.61, 35.61) -2.06 (-2.18, -1.95) 6.80(3.92, 9.68)
Risperidone generic market share (%) 2.19(2.03, 2.34) 37.65(34.60, 40.69) -2.04(-2.20, -1.88) 11.13(6.79, 15.48)
Clozapine generic market share (%) 0.07(-0.02, 0.17) 2.22(0.30, 4.14) -0.25(-0.36, -0.13) -0.97(-3.75, 1.81)
Portugal
Total sales growth per 100,000 population (SU) - -4686 (-8913, -458) - -4686 (-8758, -613)
Risperidon generic market share (%) -0.08(-0.15, 0.01) 2.16 (0.76, 3.57) 0.19(0.06, 0.31) 4.59(2.67, 6.51)
Amisulpride generic market share (%) - 12.23(9.61, 14.85) 0.82(0.56, 1.09) 22.95 (21.01, 24.90)
CI = confidence interval, SU = standard unit.
Data source: IMS MIDAS®, January 2007 and December 2011, IMS Health Incorporated. All Rights Reserved.
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series estimates of the retail generic market shares (percentage, standard units of generics per month) of the three top active substances in the
antipsychotic market before and after the phase-in period of the policy interventions in Finland and Portugal. Data source: IMS MIDAS®, January
2007 and December 2011, IMS Health Incorporated. All Rights Reserved.
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changes in reimbursement rates, and a generic campaign
resulted in a major increase in generic market share only
for one molecule (amisulpride); generic risperidone already
dominated the market prior the policy interventions.
The two countries’ policy trajectories differed: The refer-
ence price system in Finland was prepared well in advance
of implementation. In April 2003 Finland introduced
mandatory generic substitution, requiring pharmacists to
substitute higher-priced branded medicines with less-
costly generic versions. The mandatory generic substitu-
tion at the time decreased average prices of substitutable
medicines by more than 10% [42,43]. Among the key
elements of guaranteeing a successful implementation of a
generic policy is a transparent implementation process
accompanied by early involvement of all stakeholders,
such as doctors and pharmacists, as well as a detailed
methodology and positive perceptions of patients towards
generics [44,45]. System changes such as reference price
systems are intended to facilitate changes in behaviors of
patients and health providers by encouraging them to be
more price-sensitive; in a reference price system patients
have to pay out-of-pocket the difference between the ref-
erence price and the actual price, generating an incentive
for patients to request a medicine that is priced at or
below the reference price, usually a generic product. We
demonstrated that Finland achieved the reference price
policy goal of greater generic utilization. We also observed
a reduction in utilization post-policy, which was gradual,
not statistically significant and relatively smaller compared
to Portugal.
In Portugal, we found that the mix of cost-containment
measures that were ongoing before and after October
2010 led to a sudden, slight, statistically significant overall
decrease of retail antipsychotic use – assuming a three
tablet per day oral treatment, policy changes may have re-
sulted in 6 to 97 fewer treatment days among 100,000
people per month in Portugal. We cannot disentangle
which of the policies may have exerted most influence on
utilization, or which population subgroups may have
decreased utilization. At the end of 2010, Portugal was
urgently seeking ways to cut public spending on medicines
as the Portuguese economy had not recovered from the
recession in 2009. Some of the policy measures shifted
costs to patients by lowering reimbursement levels and re-
quiring higher co-payments [46]. Shortly after the change
in co-payment rates in 2010, public concerns in Portugal
emerged that higher co-payments would have a negative
impact on utilization of essential medicines including
antipsychotic medicines [47]. Given that following the
recession-induced policy package, patients in Portugal
were no longer exempt from co-payments based on
indication or other characteristics, it is reasonable to as-
sume that sicker, poorer patients would be less likely to
afford co-payment increased and more likely to decrease
utilization.
In both countries, one of the most frequently sold ac-
tive substances did not increase in generic market share
(in Finland clozapine and in Portugal risperidone), which
we attribute to different circumstances. Since clozapine
use is associated with potentially life-threatening side
effects, many countries have implemented strict prescrip-
tion guidelines limiting clozapine prescriptions only to
treatment-resistant schizophrenia patients [48]. Clinicians
may also be reluctant to switch patients from clozapine to
generic alternatives due to reports of worsening clinical
status associated with generic substitution [49]. These
clinical aspects may explain why clozapine use remained
somewhat constant during the study period. Furthermore,
the originator manufacturer of clozapine lowered its price
to the reference price after the introduction of the refer-
ence price system, so there may not have been any finan-
cial incentive for patients to ask for a lower priced generic.
Prescribing guidelines for the treatment of schizophrenia
in Portugal recommended the use of risperidone and gen-
eric risperidone already had 90% of the market share prior
to the policy interventions [50]. Due to the severity of the
illness and strict prescribing guidelines the generic cam-
paign in Portugal probably did not lead to increases in
generic market share of this therapeutic group. Under
these circumstances, the generic policies did not have an
observable additional effect.
Adherence to therapies is especially challenging for
patients on antipsychotic medicines. Increases in cost-
sharing likely put additional pressure on vulnerable pop-
ulations of low-income and chronically ill patients that
may lead to lower utilization and worse health outcomes
[51-53]. Soumerai et al. demonstrated that limits on
coverage for the costs of outpatient prescription medi-
cines can increase use of mental health services for acute
exacerbations among low-income patients with chronic
mental illnesses and result in increased costs to payers.
He suggested that policy changes that pose substantial
risks to vulnerable populations should undergo careful
evaluation before their widespread adoption [54]. More
research is needed on the potential unintended effects of
reductions in reimbursement rates, as part of pharma-
ceutical sector responses to the recession, on utilization
and long-term health outcomes.
IMS data represent country pharmaceutical markets
consistently over time. They allow application of the
strongest quasi-experimental research design for evaluat-
ing system-wide policy interventions. Nevertheless, the
data pose some limitations. They do not allow us to de-
termine the actual number of prescriptions issued or the
actual amounts that third-party payers or patients pay
for each medicine. We also did not have access to actual
numbers of patients receiving antipsychotics nor could
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were prescribed (including whether this was on- or off-
label), or the characteristics of patients receiving them.
Decreases in antipsychotic medicines use may have oc-
curred among populations for whom the drugs were not
indicated (constituting a desirable policy effect) or pref-
erentially among poorer, sicker populations in need of
the medicines (constituting an undesirable, inequitable
policy effect). Other policies implemented at the same
time could have confounded our analyses; to guard
against this possibility, we have verified our policy data
with policy makers from the PPRI network in each
country. We recognize that we could not address the
increased market share resulting from generics being on
the market for a longer period of time, nor could we
account for any economic incentives during this period
that might have influenced prescribers’ behavior. We
suggest that future research on the impacts of cost-
containment policies on access to antipsychotics and
other therapeutic classes should examine national pre-
scribing data and national household survey data and
use mixed methods to understand rationales for pre-
scriber and patient behavior.
Conclusions
Different policy approaches to contain pharmaceutical
expenditures in the study countries had different
intended – increased use of generics – and likely unin-
tended – slightly decreased overall sales possibly consist-
ent with decreased access to needed medicines – impacts.
Especially the latter finding stresses the importance of
examining the long-term effects of policy measures as
increases in cost-sharing may have beneficial short-term
impacts on public spending, but might also entail unin-
tended long-term reductions in utilization, particularly
for economically disadvantaged populations.
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